Stock 4569 KYORIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings KYORIN Pharmaceutical Co., Ltd.

Equities

4569

JP3247090008

Delayed Japan Exchange
Other stock markets
 01:19:49 28/06/2024 BST 		5-day change 1st Jan Change
1,701 JPY -0.06% Intraday chart for KYORIN Pharmaceutical Co., Ltd. +0.12% -4.55%
2023 ATyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan MT
2021 KYORIN Holdings, Inc.(TSE:4569) dropped from S&P Japan 500 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The company appears to be poorly valued given its net asset value.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company sustains low margins.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
KYORIN PHARMACEUTICAL CO., LTD. Stock KYORIN Pharmaceutical Co., Ltd.
-4.55% 613M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.95% 811B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.62% 640B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.98% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.08% 333B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.05% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.30% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.41% 225B
A+
NOVARTIS AG Stock Novartis AG
+12.47% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.91% 168B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4569 Stock
  4. Ratings KYORIN Pharmaceutical Co., Ltd.